86
Participants
Start Date
May 23, 2017
Primary Completion Date
October 7, 2020
Study Completion Date
November 9, 2020
secukinumab
secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
placebo
Matched placebo to AIN457 for use in the double blind Treatment Period 2
Novartis Investigative Site, Laken
Novartis Investigative Site, Brussels
Novartis Investigative Site, Panorama
Novartis Investigative Site, Cape Town
Novartis Investigative Site, Ghent
Novartis Investigative Site, Berlin
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Genova
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Krakow
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Valencia
Novartis Investigative Site, Saint Augustin
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Napoli
Novartis Investigative Site, Boise
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Portland
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Voronezh
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Ankara
Novartis Investigative Site, Bristol
Novartis Investigative Site, Glasgow
Novartis Investigative Site, Liverpool
Novartis Investigative Site, London
Novartis Investigative Site, Nottingham
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY